Funding for this research was provided by:
Fondation de l'Avenir pour la Recherche Médicale Appliquée (ET3-714)
Fondation des gueules cassées
Received: 21 December 2017
Revised: 24 February 2018
Accepted: 15 March 2018
First Online: 27 July 2018
Ethics approval and consent to participate
: The patient was included in the CELLCORDES phase I clinical trial (EudraCT number 2015–000238-31; ExternalRef removed NCT02622464, first posted 4 December 2015). She gave written consent to participate in the study. The study was approved by the French National Agency for Medicines and Health Products Safety and the French Ethics Committee (CPP Sud Méditerranée V, 04/21/2015).
: The patient gave her consent for publication of her data.
: The authors declare they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.